Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALPG | P10696 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28433227 | 1.00 | IDO1 (0.42) | IDO1TDO2AOC3HDAC3HDAC4 | |
| SCHEMBL7563025 | 0.77 | IDO1 (0.46) | IDO1TDO2AOC3HDAC3HDAC4 | |
| SCHEMBL3544057 | 0.77 | IDO1 (0.46) | IDO1TDO2AOC3HDAC3HDAC4 | |
| SCHEMBL11603843 | 0.77 | IDO1 (0.46) | IDO1TDO2AOC3HDAC3HDAC4 | |
| SCHEMBL597442 | 0.77 | IDO1 (0.46) | IDO1TDO2AOC3HDAC3HDAC4 | |
| SCHEMBL4454516 | 0.74 | IDO1 (0.44) | IDO1TDO2AOC3HDAC3HDAC4 | |
| SCHEMBL28092406 | 0.74 | ESR1 (0.50) | KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1253478 | 0.74 | ESR1 (0.50) | KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL21994503 | 0.74 | IDO1 (0.44) | IDO1TDO2AOC3HDAC3HDAC4 | |
| SCHEMBL5006070 | 0.72 | TSHR (0.46) | IDO1TDO2AOC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | claimed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | claimed |
| CN-102690269-B | Trifluoro methyl substituted quinoline or quinoxaline compound and preparation method thereof, and pharmaceutical composition containing the compound and purpose thereof | SHANGHAI INST MATERIA MEDICA | 2015-01-07 | — | — | CN | claimed |
| CN-102690269-A | Trifluoro methyl substituted quinoline or quinoxaline compound and preparation method thereof, and pharmaceutical composition containing the compound and purpose thereof | SHANGHAI INST MATERIA MEDICA | 2012-09-26 | — | — | CN | claimed |
| CN-102548982-A | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2012-07-04 | — | — | CN | claimed |
| CN-101993416-A | Quinoline compound and preparation method thereof, medicament combination containing compound and application of compound | SHANGHAI INST MATERIA MEDICA | 2011-03-30 | — | — | CN | claimed |
| WO-2006127024-A1 | REAGENTS AND METHODS FOR LABELING TERMINAL OLEFINS | EISAI CO. LTD. (JP) | 2006-11-30 | — | — | WO | claimed |
| US-20060045846-A1 | Reagents and methods for labeling terminal olefins | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-03-02 | — | — | US | claimed |
| CN-1130630-A | Pyridylthiazolidinecarboxylic acid amide derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 1996-09-11 | — | — | CN | claimed |
| CN-1074682-A | Pyridylthiazolidine carboxylic acid amide derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1993-07-28 | — | — | CN | claimed |
| EP-4330236-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-0034894-B1 | 2-(1-PIPERAZINYL)-2,4,6-CYCLOHEPTATRIEN-1-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES USED IN THE PROCESSES AND THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE DERIVATIVES | AYERST, MCKENNA AND HARRISON INC. (CA) | 1984-09-12 | — | — | EP | disclosed |
| US-4337341-A | 4a-Aryl-octahydro-1H-2-pyrindines | ELI LILLY AND COMPANY (US) | 1982-06-29 | — | — | US | disclosed |
| EP-0034894-A2 | 2-(1-Piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives, processes for their preparation, intermediates used in the processes and the preparation thereof and pharmaceutical compositions containing the derivatives | AYERST, MCKENNA AND HARRISON INC. (CA) | 1981-09-02 | — | — | EP | disclosed |
| EP-0002937-A1 | Novel pyrindines and their preparation, formulations and use | ELI LILLY AND COMPANY (US) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | IDO1 2259/4885TDO2 2264/4885AOC3 2454/4885 |
| US-20060045846-A1 | Reagents and methods for labeling terminal olefins | EEF2, RNF168, REL | IDO1 2111/4885TDO2 1397/4885AOC3 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.